OncoBreak: 'Am I a Survivor?' T-Cell Therapy Expands; Bogus Breast Screening

FG_AUTHORS: MedPage Today

Many patients with cancer ask, "Am I a survivor?" An oncologist offers personal and professional insights into the possible answers. (ASCO Connection)

Clinical investigation of adoptive T-cell therapy (CAR T) quickly expanded beyond hematologic cancers to solid tumors. (Roswell Park Cancer Institute)

Certain nerve cells appear to stimulate blood vessel development that helps fuel the growth of prostate cancer. (Albert Einstein College of Medicine)

Who should be screened for lung cancer? The American Cancer Society offers information and advice.

A clinical trial in breast cancer will evaluate the potential benefits of combining focused ultrasound with immunotherapy. (Focused Ultrasound Foundation)

Peyronie's disease, a pathologic curvature of the penis, increases men's risk for several types of cancer. (Newsweek)

Nonsmoking employees of one Japanese company get an extra six days off each year. (New York Times)

Nanoparticles that deliver immunotherapeutic agents might facilitate "hit-and-run" treatment -- temporary engagement between therapy and tumor cells, as opposed to continuous treatment. (Fred Hutchinson Cancer Research Center)

The FDA granted orphan drug status to the IDO-pathway inhibitor indoximod for treatment of stage IIb-IV melanoma. (NewLink Genetics)

Beware of bogus breast cancer screening tests. (Newsweek)

One of every 10 patients who have surgery for cancer subsequently develops opioid dependence. (University of Michigan Health)

The composition of a patient's gut bacteria (microbiome) may influence the toxicity of chemotherapy for colorectal cancer. (Albert Einstein College of Medicine)

2017-11-02T12:30:00-0400

Read more http://www.medpagetoday.com/publichealthpolicy/ethics/68981

PUA Social Network

Twitter Facebook

Contact us

The Philippine Urological Association,Inc
3rd floor. PCS Bldg., 992 EDSA, Quezon City,
Metro Manila, PHILIPPINES 1105
View Map

+632-9256740 
+632-4544439
+63917-5244456

eMail us